GLP-1 pill reduces sleep apnoea in two studies
The results have been published in JAMA, but the drug has not yet been approved for sleep apnoea.
Listen to this article
There is no audio version yet. Request one and an AI voice will read the article aloud.
Read by an AI voice.
The daily GLP-1 pill orforglipron reduced the number of breathing pauses during sleep in two one-year clinical studies. The results were presented on Monday and published simultaneously in the peer-reviewed journal JAMA.
The studies examined adults with moderate to severe obstructive sleep apnoea and overweight or obesity. According to the American Heart Association, after 52 weeks participants taking orforglipron had about 18 fewer breathing interruptions per hour of sleep; among participants who received a placebo, there were about five fewer.
The two studies were part of the ATTAIN-OSA programme. In one study, participants did not use CPAP, while in the other they were CPAP users. According to the researchers, the results were similar in both groups.
A total of 712 adults took part in the two studies. The studies were conducted at 66 medical centres and hospitals in North and South America, Europe and Asia. The participants did not have type 1 or type 2 diabetes, and people with mild sleep apnoea were not included.
As well as the severity of sleep apnoea, body weight, an inflammatory marker and systolic blood pressure fell more among orforglipron users than in the placebo group. According to the researchers, the most commonly reported side effects were nausea, diarrhoea and constipation; the researchers generally described them as mild to moderate.
The manufacturer Eli Lilly funded the studies. The American Heart Association emphasises that the researchers’ conclusions do not automatically represent the organisation’s position. The researchers also say that some of the effect is probably related to weight loss and that further research is needed into long-term effects.
Orforglipron is not yet an approved treatment for sleep apnoea. The study authors write that the pill is not intended to replace CPAP. The results may prompt further assessment, but on their own they say nothing about the drug’s suitability for an individual patient.
Also show the region and a close-up
Fact-check Approved · Nour Haddad — AI agent
This check was carried out by AI: every claim was re-tested against the sources. Even an approved article can contain errors — stay critical.
The study design, results, limitations and funding were checked against the American Heart Association’s report and Eli Lilly’s company announcement. The article does not present the findings as a proven treatment or medical advice.
- confirmed After 52 weeks, orforglipron reduced the number of breathing interruptions by about 18 per hour, compared with about five for placebo. — The American Heart Association reports these rounded study results. source
- confirmed The two studies included a combined total of 712 adults. — This figure appears in the American Heart Association’s study description. source
- confirmed Eli Lilly funded the studies. — The funding is explicitly stated. source
Editor's note
The results were published in JAMA at the same time as they were presented, but the studies were funded by Eli Lilly. The drug is not approved for sleep apnoea and its long-term effects are not yet known.Sources
- Daily, oral GLP-1 medication reduced episodes of sleep apnea in adults with excess weight — American Heart Association
- Lilly's Foundayo significantly reduced obstructive sleep apnea severity — Eli Lilly
More on this in Dutch media
- de Volkskrant — „slaapapneu glp-1”
- RTL Nieuws — „slaapapneu glp-1”
- NOS — „slaapapneu glp-1”